Login / Signup

The use of a systems approach to increase NAD + in human participants.

John D HendersonSophia N Z QuigleyShruti S ChachraNichola ConlonDianne Ford
Published in: npj aging (2024)
Reversal or mitigation against an age-related decline in NAD + has likely benefits, and this premise has driven academic and commercial endeavour to develop dietary supplements that achieve this outcome. We used a systems-based approach to improve on current supplements by targeting multiple points in the NAD + salvage pathway. In a double-blind, randomised, crossover trial, the supplement - Nuchido TIME+® (NT) - increased NAD + concentration in whole blood. This was associated with an increase in SIRT1 and an increase in nicotinamide phosphoribosyltransferase (NAMPT) in peripheral blood mononucleocytes, lower concentrations of pro-inflammatory cytokines in plasma, including a reduction in interleukin 2 (IL2), a reduction in glycated serum protein and a shift in the glycosylation profile of immunoglobulin G (IgG) toward a younger biological age, all of which are likely to promote a healthier ageing trajectory.
Keyphrases
  • peripheral blood
  • clinical trial
  • open label
  • study protocol
  • endothelial cells
  • double blind
  • climate change
  • placebo controlled
  • phase ii
  • induced pluripotent stem cells
  • ischemia reperfusion injury